First published 10/1/2026, 6:23:15 PM · Last updated 10/1/2026, 6:23:15 PM

Oral administration of a high-branched Rhamnogalacturonan-I type pectin from Lycium barbarum regulates immune responses via small intestine-immune and colon-immune dual axis in cyclophosphamide-treated mice

An Elsevier journal article (2026-10-01) reports that oral delivery of a high-branched rhamnogalacturonan-I pectin from Lycium barbarum modulated immune responses in cyclophosphamide-treated mice through both small intestine and colon immune pathways. The source excerpt provided no additional methodological, quantitative, or location details.

Categories: science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 5/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 7/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The report indicates a potential preclinical immunomodulatory effect of a Lycium barbarum-derived pectin in a chemotherapy-immunosuppressed mouse model.

Sources

Oral administration of a high-branched Rhamnogalacturonan-I type pectin from Lycium barbarum regulates immune responses via small intestine-immune and colon-immune dual axis in cyclophosphamide-treated mice

Report an issue